Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)

v3.7.0.1
Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Expenses        
Research and development $ 1,086,107 $ 790,323 $ 2,939,746 $ 2,183,355
General and administrative 698,125 630,226 2,586,050 1,994,923
Operating expenses 1,784,232 1,420,549 5,525,796 4,178,278
Other loss (income)        
Change in fair value of stock option and derivative liabilities 77,479 (276,584) (58,501) 943,050
Change in fair value of derivative liability due to change in warrant terms 7,000 270,965
Foreign exchange 6,897 (10,523) 13,726 16,257
Interest income (148) (41) (249) (71)
Other (income) loss 84,228 (280,148) (45,024) 1,230,201
Net and comprehensive loss for the period 1,868,460 1,140,401 5,480,772 5,408,479
Computation of basic loss per share        
Net and comprehensive loss for the period 1,868,460 1,140,401 5,480,772 5,408,479
Series B Preferred stock dividend 209,811 676,865
Net and comprehensive loss available to common stockholders $ 2,078,271 $ 1,140,401 $ 6,157,637 $ 5,408,479
Basic and fully diluted loss per share $ 0.18 $ 0.10 $ 0.54 $ 0.50
Basic weighted average number of shares 11,574,052 11,077,275 11,432,376 10,896,887